Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14930399 | 0.84 | SMN1; SMN2 (0.51) | SMN1; SMN2ATML3MBTL1GAAHTT | |
| SCHEMBL14912963 | 0.83 | SMN1; SMN2 (0.47) | SMN1; SMN2ATML3MBTL1GAAHTT | |
| SCHEMBL14926281 | 0.82 | PDE2A (0.49) | SMN1; SMN2ATML3MBTL1GAAHTT | |
| SCHEMBL2214941 | 0.77 | HPGD (0.50) | SMN1; SMN2ATML3MBTL1GAAHTT | |
| SCHEMBL17473498 | 0.76 | SMN1; SMN2 (0.41) | SMN1; SMN2ATML3MBTL1GAAHPGD | |
| SCHEMBL13817563 | 0.75 | HPGD (0.48) | SMN1; SMN2ATML3MBTL1GAAHTT | |
| SCHEMBL17076827 | 0.75 | HPGD (0.48) | SMN1; SMN2ATML3MBTL1GAAHTT | |
| SCHEMBL21017704 | 0.74 | GAA (0.43) | SMN1; SMN2ATML3MBTL1GAAHSP90AA1 | |
| SCHEMBL27228782 | 0.74 | KDM4E (0.62) | SMN1; SMN2ATML3MBTL1HTTHPGD | |
| SCHEMBL17473310 | 0.73 | GAA (0.46) | SMN1; SMN2ATML3MBTL1GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2980089-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-12-20 | — | — | EP | disclosed |
| US-20170174682-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-22 | — | — | US | disclosed |
| US-20170174682-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-22 | — | — | US | disclosed |
| US-20170174682-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-22 | — | — | US | disclosed |
| US-9637483-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-02 | — | — | US | disclosed |
| US-9637483-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-02 | — | — | US | disclosed |
| US-20160039811-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-11 | — | — | US | disclosed |
| US-20160039811-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-11 | — | — | US | disclosed |
| EP-2980089-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174682-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | SMN1; SMN2 286/4885ATM 2230/4885L3MBTL1 2432/4885 |
| US-20160039811-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | SMN1; SMN2 286/4885ATM 2230/4885L3MBTL1 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.